Spaulding Clinical Announces New Joint Partnership for Global Studies with Eurofins Optimed Clinical Research
Eurofins Optimed Clinical Research
and
Spaulding Clinical Research
announced a joint partnership agreement. This partnership leverages the strengths of both companies and facilitates collaboration on integrated clinical services to engage pharmaceutical clients who demand a global footprint.
"The culture of excellence and research facilities designed to execute high-quality studies was very impressive to our team. We felt immediately comfortable with the Optimed clinical team and witnessed their efficient execution of studies," states Daniel Selness, General Manager and Senior Vice President of Operations. "We were very impressed that Spaulding achieved ISO certification, which is not common among US clinical research facilities. Their systems approach with Electronic Data Capture is something that we have been looking to implement, so the partnership will allow us to consider how to collaborate more closely as these systems are put in place," states Yves Donazzolo, MD, CEO and President of Optimed.
Eurofins Optimed and Spaulding Clinical offer a full range of global services to the Pharmaceutical industry and Biotechnology companies from study design through study execution/conduct, data management, statistical analysis, and medical writing. Both companies excel in TQT, first-in-human, multiple rising dose, bioavailability/bioequivalence, drug interaction, food effect studies and Proof-Of-Concept studies in patients.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
